Opaleye Management Inc. Has $4.45 Million Holdings in 4D Molecular Therapeutics, Inc. $FDMT

Opaleye Management Inc. increased its stake in shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) by 197.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 334,437 shares of the company’s stock after buying an additional 222,146 shares during the quarter. Opaleye Management Inc. owned 0.61% of 4D Molecular Therapeutics worth $4,448,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of FDMT. Engineers Gate Manager LP grew its position in 4D Molecular Therapeutics by 132.0% in the second quarter. Engineers Gate Manager LP now owns 68,206 shares of the company’s stock valued at $907,000 after acquiring an additional 38,806 shares during the period. California State Teachers Retirement System lifted its holdings in shares of 4D Molecular Therapeutics by 239.5% during the second quarter. California State Teachers Retirement System now owns 8,246 shares of the company’s stock valued at $110,000 after acquiring an additional 5,817 shares during the period. AXQ Capital LP acquired a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter valued at $186,000. Headlands Technologies LLC boosted its stake in shares of 4D Molecular Therapeutics by 20.6% in the 2nd quarter. Headlands Technologies LLC now owns 19,238 shares of the company’s stock valued at $256,000 after purchasing an additional 3,282 shares in the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter worth about $148,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

Insider Buying and Selling at 4D Molecular Therapeutics

In related news, insider Scott Bizily sold 9,810 shares of the firm’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total value of $117,720.00. Following the transaction, the insider owned 8,617 shares in the company, valued at $103,404. This trade represents a 53.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $10.47, for a total value of $1,201,390.62. Following the completion of the sale, the insider owned 942,485 shares of the company’s stock, valued at approximately $9,867,817.95. The trade was a 10.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 199,158 shares of company stock worth $2,229,161 in the last ninety days. 7.90% of the stock is currently owned by insiders.

4D Molecular Therapeutics Stock Performance

FDMT stock opened at $13.49 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 8.03 and a quick ratio of 8.03. The company has a 50 day moving average price of $12.64 and a 200 day moving average price of $10.67. 4D Molecular Therapeutics, Inc. has a fifty-two week low of $6.47 and a fifty-two week high of $16.93. The stock has a market capitalization of $745.19 million, a PE ratio of -5.13 and a beta of 2.74.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). The firm had revenue of $3.78 million for the quarter, compared to analyst estimates of $3.62 million. 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%. Analysts forecast that 4D Molecular Therapeutics, Inc. will post -4.09 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on FDMT shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Friday, July 17th. B. Riley Financial restated a “buy” rating on shares of 4D Molecular Therapeutics in a research report on Monday, August 17th. Chardan Capital raised shares of 4D Molecular Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. HC Wainwright reaffirmed a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a report on Monday, July 20th. Finally, The Goldman Sachs Group reiterated a “buy” rating and issued a $32.00 target price on shares of 4D Molecular Therapeutics in a research note on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $29.62.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.